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Abstract
Background: It remains unknown whether primary ocular adnexal extranodal marginal zone B-
cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a homogeneous entity,
as there are few reports of the results of cytogenetic or molecular analyses of these tumors.
Methods: We performed interphase fluorescence in situ hybridization (FISH) analysis to detect
translocations and aneuploidy in 34 cases of primary ocular adnexal MALT lymphoma, and
reviewed the histopathological findings. Correlations between the results of FISH analysis, the
histopathological features and the clinical data were also analyzed.
Results: Among the 34 cases, FISH analysis revealed t(14;18)(q32;q21) in one case, trisomy 3 in
21 cases (62%), and trisomy 18 in 16 cases (47%). The cases with trisomy 18 had significantly more
prominent lymphoepithelial lesions (LELs) and less nodularity in the tumors. In regard to the clinical
correlations, tumors with trisomy 18 were observed predominantly in females and younger
patients; also, in the majority of the cases, the tumor was of conjunctival origin. All the cases with
recurrence showed trisomy 18 in the tumor.
Conclusion: Primary ocular adnexal MALT lymphoma is a significantly heterogeneous entity.
Cases with trisomy 18 may have unique clinicopathological features.
Background
Since the first description by Isaacson and Wright in 1983,
MALT lymphoma has been recognized as a distinct entity
of low-grade B-cell lymphoma; it is described as a separate
entity in the revised European-American lymphoma
(REAL) classification and also in the more recent classifi-
cation by the World Health Organization (WHO) [1-3].
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Various cytogenetic changes, such as t(11;18)(q21;q21),
and t(1;14)(p22;q32) and trisomy 3, 7, 12 and 18, have
been detected as recurrent chromosomal aberrations in
this tumor [4-8]. Recently, t(14;18)(q32;q21), which is
derived from fusion of the immunoglobulin heavy chain
(IgH) gene with the MALT lymphoma-associated translo-
cation (MALT1) gene has been described [9]. While it is
difficult by standard karyotypic analysis to distinguish
this translocation from that in follicular lymphoma which
is derived from fusion of the IgH gene with the bcl-2 gene,
FISH analysis is useful for the differentiation. The his-
topathological findings of MALT lymphoma have also
been reported to be heterogeneous [2,3]. The cells com-
prising the tumor may be either centrocyte-like cells, cells
resembling monocytoid B cells, small lymphocytes or
scattered immunoblasts and centroblast-like cells. There
may be various degrees of plasma cell differentiation.
Malignant lymphomas arising from the ocular adnexa
account for about 8% of all extranodal lymphomas [10].
They have been recognized as low-grade B-cell lympho-
mas which usually remain localized and follow an indo-
lent clinical course [11,12]. Several reports have suggested
that the majority of lymphomas arising from the ocular
adnexa are MALT lymphomas [13-17]. As heterogeneity
among MALT lymphomas are well known, it would also
be reasonable to expect heterogeneity in the case of ocular
adnexal MALT lymphomas; however, the significance of
the cytogenetic and histopathological differences among
the tumors is still not known. In this study, we conducted
a retrospective analysis of a large number of cases with
ocular adnexal MALT lymphoma to determine the nature
and distribution of chromosomal aberrations as evalu-
ated by FISH and the tumor grade as evaluated by his-
topathological examination, and also attempted to
determine the relationships between the clinical features,
chromosomal aberrations and the histopathological find-
ings.
Methods
Patients' samples
Archived samples of primary ocular adnexal MALT lym-
phoma at our institute between 1995 and 2003 were uti-
lized for this study. The diagnosis of MALT lymphoma
was confirmed by histopathological examination of either
biopsy specimens or surgically resected specimens of the
primary ocular adnexal lesions. In all the cases, the diag-
nosis was reviewed by two hematopathologists (YM and
AAM) according to the REAL classification or the WHO
classification. Samples for the FISH analysis were
obtained from the same primary lesions in the ocular adn-
exa.
This study was approved by the institutional review board
of National Cancer Center (16–7).
Clinical features
The clinical data were obtained from the medical records.
The sex, age, clinical stage, site of involvement, perform-
ance status (PS) according to the Eastern Cooperative
Oncology Group scale, the serum lactate dehydrogenase
(LDH) value at the time of initial presentation, and the
initial therapy were recorded. The anatomic site of
involvement was determined by the system reported by
Knowles et al. [18]. We specified lachrymal gland origin
when the gland structure could be clearly recognized in
the histopathological specimens. Chest X-ray, computed
tomography of the head/eye, neck, chest, abdomen and
pelvis, gallium scintigraphy, bone marrow and peripheral
blood examinations were performed to determine the
clinical stage. The clinical stages were determined accord-
ing to the Ann Arbor staging classifications. Disease recur-
rence was defined as an increase in the tumor size as
detected by either visual inspection or by imaging studies,
or appearance of new tumor lesions at distant sites.
FISH analysis
The tissue FISH procedure was performed in formalin-
fixed paraffin sections in accordance with the procedure
described by Sekiguchi et al. [19]. We applied six kinds of
probes for the FISH analysis. All of the probes were pur-
chased from the same manufacturer (Vysis, Downers
Grove, IL, USA). To detect t(14;18)(q32;q21), we used the
LSI IGH/MALT1 Dual Color, Dual Fusion Translocation
Probe. To detect t (11;18)(q21;q21), we used the LSI
API2/MALT1 Dual Color, Dual Fusion Translocation
Probe. All the specimens were examined using the IGH/
MALT1 probe to detect t(14;18)(q32;q21). In cases in
which extra MALT1 signals were detected, we used the
API2/MALT1 probe to detect t(11;18)(q21;q21). To detect
amplification or deletion of chromosomes 3,7,12 and 18,
we used the CEP 3, 7, 12 and 18 Spectrum Orange or
Green Probes which hybridize to the centrometric region
of the chromosomes.
We also analyzed 4 reactive lymphomatous lesions of the
ocular adnexa as a negative control and the threshold was
determined for each probe by counting the number of sig-
nals or fusions in one nucleus per 100–200 cells. The sig-
nal frequency thresholds were determined as the mean
plus 3 standard deviations. Each specimen was examined
independently by three investigators (YK, YY, and KT).
The number of signals or fusions in one nucleus was
counted in 200 cells, and when the results were judged to
be the same, the specimen was considered as being suc-
cessfully stained and included in this study.
Histopathological review
Each hematoxylin eosin (HE)-stained specimen was his-
tologically reviewed by two of us (KT and YM). In addi-
tion to histopathology, the paraffin-embedded sectionsBMC Cancer 2006, 6:249 http://www.biomedcentral.com/1471-2407/6/249
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were also subjected to immunostaining for CD3 by the
standard avidin – biotin method using monoclonal anti-
CD3 antibody (PS1, Novocastra, Newcastle-upon-Tyne,
UK) as the primary antibody. Immunophenotypic analy-
sis revealed that the tumor cells of MALT lymphoma were
positive for CD20 and negative for CD5, CD10 and cyclin
D1. Frequently but not universally observed morphologi-
cal features of primary ocular adnexal MALT lymphomas
were examined for and categorized as follows: the finding
of an abundance of plasma cells, monocytoid B cells and
reactive CD3-positive T cells in none of the areas of the
tumor was denoted as negative (-), in less than 30% of the
tumor area was denoted as focally positive (+), in 30–60%
of the tumor area was denoted as positive (2+), and in
60% or more of the tumor area was denoted as strongly
positive (3+). The finding of residual reactive germinal
centers, large lymphoid cells, polykaryocytes, brown-pig-
ment-laden histiocytes, mitotic cells, lymphoepithelial
lesions (LELs) and Dutcher bodies was categorized as neg-
ative (-), focally positive (+), or positive (2+) when it was
absent, present but inconspicuous, or very conspicuous,
respectively. The degree of nodularity was classified as
negative (-) in cases without discernible vague nodularity,
focally positive (+) in cases with vague nodularity, and
positive (2+) in cases showing definite nodularity.
Statistical analysis
Statistical analysis was performed using the SPSS software
for Windows, version 13.0. The correlations between the
clinical features, results of FISH analysis and the morpho-
logical features were analyzed by Fisher's exact test. Sur-
vival was censored at the time of the last documented
follow-up date. The overall survival period and time to
recurrence were calculated using the Kaplan-Meier
method and compared by the log-rank test.
Results
Patient characteristics and outcomes
The characteristics of the patients are shown in Table 1.
The median age was 57 years (range, 15 to 90 years), and
there were 23 males and 11 females. There were three age
peaks; 8 patients who were less than 40 years of age, 12
patients who were 50 years of age and 14 patients who
were more than 60 years of age.
The most frequently involved site was the orbit (62%). In
26 patients (76%), the disease was unilateral, whereas in
eight patients (24%) it was bilateral. Almost all patients
had localized disease and a serum LDH in the normal
range. None of the patients had any manifestations of
autoimmune diseases. The initial therapies varied among
the patients: 21 patients (66%) received radiation only,
three (9%) received chemotherapy, three (9%) received
chemotherapy combined with radiation therapy and 5
(16%) were observed under a watch-and-wait policy. Two
patients were lost to follow-up after the diagnosis. After a
median follow-up duration of 31 months (range, 8 to 118
months), all 32 patients were alive and the disease
recurred in five patients. There were no significant differ-
ences in terms of the sex or age of the patients, site of
involvement, laterality, initial therapy, stage, or the serum
LDH level at the time of initial presentation (data not
shown).
FISH analysis and its relationship to clinical factors
The signal frequency thresholds were determined as the
mean plus 3 standard deviations (SD). The mean values of
more than two signals for the CEP 3, 7 and 18 probes were
2.50%, 0.67% and 1.75%. The thresholds of the CEP 3, 7
and 18 probe signals were 4.23%, 2.40%, and 3.25%.
IgH/MALT1 and API2/MALT1 fusions and more than two
signals for CEP 12 probe were not observed for any of the
4 control samples. Based on these results, we decided to
set a cut-off value of 5% for all the probes to reduce the
incidence of false-positive results.
The results of FISH analysis are shown in Table 2. We
defined a case as having trisomy when three centromeres
were recognized in the FISH analysis. Only one case was
positive for t(14;18)(q32;q21) (Fig. 1). There were 21
Table 1: Patient characteristics
No. of patients (n = 34)
Sex
Male/Female 23/11
Age (years)
Median/Range 57/15–90
Site of involvement
Conjunctiva 9
Orbit 21
Lachrymal gland 4
Laterality
Right 13
Left 13
Bilateral 8
Stage
I, II 31
III, IV 3
LDH>normal 5
Initial therapy*
Radiation 21
Chemotherapy 3
Chemotherapy + Radiation 3
Observation 5
* Two patients lost to follow-up after the diagnosis.BMC Cancer 2006, 6:249 http://www.biomedcentral.com/1471-2407/6/249
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(62%) cases with trisomy 3, 16 (47%) cases with trisomy
18 (Fig. 2), and 8 (24%) cases with both. There were two
cases with trisomy 7 and no cases with trisomy 12. The
one patient who showed extra MALT1 signals, which are
suggestive of MALT1 gene splitting, was negative for
t(11;18)(q21;q21). This case did not exhibit extra signals
of centromere 18 or splitting of the MALT1 gene with the
use of the MALT 1 breakapart probe, thus, MALT1 gene
amplification was suggested.
The relationship between the clinical factors of the
patients and the detection of trisomy 18 is shown in Table
3. Patients with trisomy 18 tended to be female, younger
than 50 years old and most frequently showed involve-
ment of the conjunctiva. None of the cases with trisomy
18 showed involvement of the lachrymal gland. Patients
with trisomy 3 tended to be older than 50 years of age,
however, no other significant correlation with the clinical
features was observed (data not shown). There were also
no significant correlations between other chromosomal
aberrations and the clinical features.
The disease recurred in five cases, and all of these cases
had trisomy 18. As shown in Fig. 3, there was a significant
difference in the time to recurrence between patients with
and without trisomy 18. On the other hand, as shown in
Fig. 4, there was no significant difference in the time to
recurrence between patients with and without trisomy 3.
There were also no significant correlations between any of
the other chromosomal aberrations and the time to recur-
rence (data not shown).
Results of the histological review and the relationship 
among the clinical features, results of FISH analysis and 
the histopathological findings
Table 4 shows that the morphological features were heter-
ogeneous, and the grades of the histopathological changes
in the tumor varied. We tried to extract factors that might
potentially influence the histopathological characteristics
of the tumors: we found that the morphological character-
istics were related to the site of involvement. Table 5
shows that cases with involvement of the conjunctiva
were associated with specific morphological features:
these tumors showed less nodularity (almost diffuse) and
Representative result of fluorescence in situ hybridization  analysis Figure 2
Representative result of fluorescence in situ hybridization 
analysis. Trisomy 18 is present as detected by the CEP 18 
Orange Probe. Three orange signals are seen in one cell 
(shown with the yellow arrowhead).
Table 2: Results of fluorescence in situ hybridization analysis
No. of Patients (%) (n = 34)
t(11;18)(q21;q21) 0 (0%)
t(14;18)(q32;q21) 1(3%)
trisomy 18* 16 (47%)
trisomy 3** 21 (62%)
trisomy 7 2 (6%)
trisomy 12 0 (0%)
MALT 1 gene amplification 1 (3%)
Normal 3 (9%)
* There were eight cases with trisomy 18 alone and eight cases with 
trisomy 18 and trisomy 3.
** There were eleven cases with trisomy 3 alone, eight with trisomy 3 
and   trisomy 18, one with t(14;18)(q32;q21), and one with MALT1 
gene   amplification.
Representative result of fluorescence in situ hybridization  analysis Figure 1
Representative result of fluorescence in situ hybridization 
analysis. IgH and MALT1 gene fusion pattern with the LSI 
IGH/MALT1 Dual Color, Dual Fusion Translocation Probe 
(Vysis, Downers Grove, IL, USA). One orange MALT1 signal 
(shown with the white arrowhead), one green IgH signal 
(shown with the black arrowhead), and two fusion IgH/
MALT1 signals are present (shown with the yellow arrow-
head).BMC Cancer 2006, 6:249 http://www.biomedcentral.com/1471-2407/6/249
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a greater abundance of polykaryocytes than tumors aris-
ing from other sites. Cases with lachrymal gland involve-
ment showed more nodularity, a greater abundance of
large lymphoid cells, and reactive T cells.
We attempted to identify the existence of any correlation
between the cytogenetic heterogeneity as revealed by FISH
analyses and the morphological features. Table 6 shows
that tumors showing trisomy 18 tended to show less nod-
Time to recurrence in relation to the presence of trisomy 3 Figure 4
Time to recurrence in relation to the presence of trisomy 3.
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Table 3: Relationship between clinical features and the presence of trisomy 18 as revealed by fluorescence in situ hybridization
No. of patients
clinical factor trisomy18 (+) (n = 16) trisomy 18 (-) (n = 18) p-value
Sex
male 9 14 0.166
female 7 4
Age
< 50 6 2 0.080
≥ 50 10 16
Site of involvement
orbit 10 11 0.099
conjunctiva 6 3
lachrymal grand 0 4
Laterality
unilateral 12 14 0.583
bilateral 4 4
Stage
I1 6 1 5 0 . 1 3 6
II-IV 0 3
LDH
normal 14 15 0.559
> normal 2 3
Time to recurrence in relation to the presence of trisomy 18 Figure 3
Time to recurrence in relation to the presence of trisomy 
18.
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p=0.050BMC Cancer 2006, 6:249 http://www.biomedcentral.com/1471-2407/6/249
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ularity, plasma cells and large lymphoid cells, and a
greater abundance of prominent LELs and mitotic cells,
residual reactive germinal centers and monocytoid B cells
as compared with tumors not showing trisomy 18.
Among these parameters, significant correlations were
observed between the cytogenetic characteristics and the
degree of nodularity and abundance of LELs. There were
no correlations between trisomy 3 or other chromosomal
aberrations with the histopathological features (data not
shown).
Discussion
A number of karyotypic abnormalities have been reported
in MALT lymphomas. Among these, t(11;18)(q21;q21)
was the most frequently encountered structural chromo-
somal abnormality resulting from the fusion of the apop-
tosis inhibitor-2 (API2) gene and the MALT1 gene at the
11q21 and 18q21 breakpoints [9,20-22]. Streubel et al.
indicated, based on the results of a FISH analysis, that
t(14;18)(q32;q21) involving IGH and MALT1 was
another frequently encountered chromosomal aberration
Table 5: Relationship between histopathological findings and the site of involvement
No. of patients No. of patients
conjunctiva orbit lachrymal grand p-value conjunctiva orbit lachrymal grand p-value
plasma cells brown-pigment-laden histiocytes
2+, 3+ 1 5 2 (-) 5 8 4
2+ < 8 16 2 0.347 (+) 4 13 0 0.074
Dutcher bodies mitotic cells
(-) 5 12 4 (-) 1 2 1
(+) 4 9 0 0.305 (+) 8 19 3 0.742
monocytoid B cells nodularity
(-) 2 4 0 (-) 5 2 0
(+) 7 17 4 0.697 (+) 4 19 4 0.017
residual reactive germinal centers lymphoepithelial lesions *
(-) 2 4 1 (-) 0 1 3
(+) 7 17 3 1.000 (+) 6 2 1 0.053
large lymphoid cells reactive T cells **
2+ 1 4 3 1+ 8 14 0
(-), 1+ 8 17 1 0.050 2+ 1 5 4 0.005
polykaryocytes
(-) 0 9 3
(+) 9 12 1 0.011
* 21 cases were not applicable.
** Two cases were not done.
Table 4: Results of the grades of the histopathological changes in all 34 cases
histopathological features No. of patients
- + 2+ 3+
plasma cells 5 21 7 1
Dutcher bodies 21 11 2 NA
monocytoid B cells 6 16 11 1
residual reactive germinal 
centers
71 3 1 4 N A
large lymphoid cells 2 24 8 NA
polykaryocytes 12 15 7 NA
brown-pigment-laden 
histiocytes
17 10 7 NA
mitotic cells 4 28 2 NA
nodularity 7 14 13 NA
lymphoepithelial lesions* 4 7 2 NA
reactive T cells** 0 22 10 0
NA: not applicable
* 21 cases were not applicable.
** Two cases were not done.BMC Cancer 2006, 6:249 http://www.biomedcentral.com/1471-2407/6/249
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in MALT lymphomas [22]. In their report, three out of
eight cases (38%) of ocular adnexal MALT lymphoma had
t(14;18)(q32;q21). Recently, the same group reported
that t(3;14)(p14.1;q32) is also a recurrently observed
chromosomal aberration in MALT lymphomas, especially
those arising from the ocular adnexa; four out of 20 cases
(20%) of ocular adnexal MALT lymphoma examined by
them had this translocation [23].
The results of the FISH analysis revealed that transloca-
tions such as t(11;18)(q21;q21) and t(14;18)(q32;q21)
were rather rare; only one case showed
t(14;18)(q32;q21). In the study by Streubel et al., nine
out of the 37 cases (24%) of ocular adnexal MALT lym-
phoma were positive for t(14;18)(q32;q21) and one out
of the 37 (3%) cases were positive for t(11;18)(q21;q21)
according to the results of FISH analysis [24]. This could
be related to the geographic or genetic background; geo-
graphic heterogeneity has been shown for follicular lym-
phoma, another type of lymphoma; this tumor
universally shows t(14;18)(q32;q21) in Europe and the
US, but this is rare in this country [18]. Alternatively, it
could merely reflect the small number of samples. More
cases are needed to draw definitive conclusions.
In contrast, we found that aneuploidy was rather com-
mon. Approximately half of all the tumors showed tri-
somy 3 and/or 18. The frequency was at the upper end of
the previously reported range of 10–50% [7,8,24]. This
high frequency could be attributed to the methodology
employed by us; we used the interphase FISH method,
which can detect cytogenetic abnormalities at a greater fre-
quency than conventional cytogenetic analysis. Since ocu-
lar adnexal MALT lymphoma is an indolent disease,
interphase FISH analysis may be a more suitable method
to detect abnormalities.
The ocular adnexal MALT lymphomas also exhibited mor-
phologic heterogeneity, and the degree varied. Several
reports revealed that the majority of ocular adnexal lym-
phomas were the MALT type. To the best of our knowl-
edge, there have been no detailed analyses of the
histopathological characteristics of ocular adnexal MALT
lymphomas [12-16]. We suggest that since we analyzed
many cases, significant morphological differences were
found between cases with trisomy 18 and those without.
The differences in the morphological features of the
tumors were related to the primary site of involvement of
the MALT lymphomas; the number of large lymphoid
cells, polykaryocytes and LELs, and the degree of nodular-
ity of the tumor varied significantly depending on the site
of origin of the tumors. It may only seem natural that
tumors arising from different sites show different mor-
phological characteristics; however, there have been no
reports focusing on this issue among ocular adnexal MALT
lymphomas, partly because of the small number of
patients. The morphological differences suggest that
Table 6: Relationship between the histopathological grades and the presence of trisomy 18 as revealed by fluorescence in situ 
hybridization
No. of patients No. of patients
trisomy 18 (+) trisomy 18 (-) p-value trisomy 18 (+) trisomy 18 (-) p-value
plasma cells brown-pigment-laden histiocytes
2+, 3+ 2 6 0.153 (-) 7 10 0.366
2+ < 14 12 (+) 9 8
Dutcher bodies mitotic cells
(-) 10 11 0.607 (-) 0 4 0.066
(+) 6 7 (+) 16 14
monocytoid B cells nodularity
(-) 1 5 0.116 (-) 6 1 0.029
(+) 15 13 (+) 10 17
residual reactive germinal centers lymphoepithelial lesions *
(-) 1 6 0.061 (-) 0 4 0.049
(+) 15 12 (+) 6 3
large lymphoid cells reactive T cells **
2+ 2 6 0.153 1+ 12 10 0.183
(-), 1+ 14 12 2+ 3 7
polykaryocytes
(-) 5 7 0.459
(+) 11 11
* 21 cases (10 trisomy 18 (+), 11 trisomy 18 (-)) were not applicable.
** Two cases (one trisomy 18 (+), one trisomy 18 (-)) were not done.BMC Cancer 2006, 6:249 http://www.biomedcentral.com/1471-2407/6/249
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MALT lymphomas of ocular adnexa origin might repre-
sent a combination of several diseases which may need to
be analyzed separately.
The morphological features were also related to the chro-
mosomal aberrations; more specifically speaking, the
presence of trisomy 18 was associated with a specific mor-
phology. The tumors in cases with trisomy 18 had more
LELs and less nodularity than those without trisomy 18.
In addition, we found that the cases with trisomy 18 had
shorter recurrence-free survivals than those without tri-
somy 18. These five cases showed no significantly differ-
ent characteristics from the other cases in terms of the sex
or age of the patient, the site of involvement, laterality,
initial therapy, stage, or the serum LDH levels at the time
of initial presentation. Trisomy 18 was strongly related to
the recurrence-free survival rate. These results show that
tumors with trisomy 18 may represent a characteristic and
one unique subgroup among primary ocular adnexal
MALT lymphomas. This recognition might compare well
with the situation of gastric MALT lymphomas with
t(11;18)(q21;q21), which constitutes a specific subgroup
in terms of the clinical setting, patient prognosis, and
morphological findings among all cases of gastric MALT
lymphoma [25,26]. The biological significance of these
specific features is unclear and further gene expression
profiling and/or competitive genomic hybridization
assays are necessary.
Recently, it has been reported that some ocular lympho-
mas may be related to Chlamydia and hepatitis C virus
infection, and the involvement of these agents might be
the reason for the heterogeneity among the tumors [27-
29]. In our series, we did not conduct these analyses, and
the relation between infection with these agents and the
existence of trisomy 18 is currently unknown.
Conclusion
We detected aneuploidy in cases of ocular adnexal MALT
lymphomas, and also morphological heterogeneity. These
results demonstrate that ocular adnexal MALT lympho-
mas differ in characteristics from those at other anatomic
sites, and also show significant heterogeneity. Also, we
suggest that these tumors showing trisomy 18 might rep-
resent a unique entity.
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